|
Re: Additional Exempt Distributions
|
2
|
Zenith Epigenetics
|
Oct 13, 2023 03:59PM
|
|
Re: Additional Exempt Distributions
|
|
Zenith Epigenetics
|
Oct 14, 2023 10:48AM
|
|
Re: Added due to participants
|
3
|
Resverlogix Corp.
|
Jun 20, 2017 12:23PM
|
|
Re: Added again....
|
|
Resverlogix Corp.
|
Jun 20, 2017 03:50PM
|
|
Re: Added a few more to the pile...
|
2
|
Resverlogix Corp.
|
Nov 09, 2017 11:59AM
|
|
Re: Accelerated approval
|
4
|
Zenith Epigenetics
|
Oct 17, 2019 12:43PM
|
|
Re: Accelerated approval
|
3
|
Zenith Epigenetics
|
Oct 17, 2019 12:48PM
|
|
Re: Accelerated approval
|
3
|
Zenith Epigenetics
|
Oct 21, 2019 02:27PM
|
|
Re: ABCA1 overexpression worsens colorectal cancer prognosis and this can be ameliorated by apabetalone
|
4
|
Resverlogix Corp.
|
Aug 24, 2018 02:53PM
|
|
Re: AAIC and MD&A
|
|
Resverlogix Corp.
|
Jul 24, 2018 12:37PM
|
|
Re: AACR 2018
|
2
|
Zenith Epigenetics
|
Mar 01, 2018 05:17PM
|
|
Re: AACR 2018
|
2
|
Zenith Epigenetics
|
Mar 06, 2018 01:15PM
|
|
Re: AACR 2018
|
2
|
Zenith Epigenetics
|
Mar 06, 2018 01:24PM
|
|
Re: AACR 2018
|
1
|
Zenith Epigenetics
|
Mar 05, 2018 03:13PM
|
|
Re: AACR 2018
|
2
|
Zenith Epigenetics
|
Feb 28, 2018 05:41PM
|
|
Re: A small drop in short interest.....
|
5
|
Resverlogix Corp.
|
Oct 21, 2015 11:03AM
|
|
Re: A Shenzhen Hepalink M&A type deal...
|
2
|
Resverlogix Corp.
|
Jan 05, 2018 06:27PM
|
|
Re: A quick note of comparison vis a vis CEO salaries....
|
6
|
Resverlogix Corp.
|
Aug 28, 2015 07:43PM
|
|
Re: A quick note of comparison vis a vis CEO salaries....
|
4
|
Resverlogix Corp.
|
Aug 29, 2015 10:28AM
|
|
Re: A little social experiment with Google Trends....
|
1
|
Resverlogix Corp.
|
Oct 31, 2017 03:59PM
|
